CDK1 and adrenal cortex carcinoma: The proposed mechanism of action is based on the fact that miR-7 acts on the proto-oncogene RAF-1 and mTOR, and miR-7 therapy inhibits cyclin-dependent kinase 1 (CDK1), which was increased in samples from patients with adrenocortical carcinoma, inversely correlated with miR-7 expression [47].